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Poster Session I S205. 39kg/M2. A more objective secondary analysis divided our pa-
tients’ BMI into quartiles was also used to explore risk threshold.
Results:The median BMI for our entire population was 33.9 (15.6-
57.6). The 100 daymortality in themyeloma andNHLpatients were
4/153 (2.6%) and 2/72 (2.7%), respectively. Using the above litera-
ture driven definitions, the data showed a significantly higher mor-
tality with increasing obesity (p\ 0.0001, see Table).
Table 1. Risk of Mortality by Degree of Obesity
BMI Group Alive Dead TotalTable 1. Characterstic
Da
Age (yrs)
CD34+ stem
cells Infused
3
WBC engraftment day
Platelet engraftment (days)
Neutopenic fever Rate
Stomatitis Rate
Median (range),
*Log-rank test ,
†U tests of study popula
y +3 group (N598) D
60.2 (36,77)
.3106 (2.5108,
1.44 x106)
3
11 (9-15)
12 (8-97)
61 (62.2%)
81 (82.7 %)tion
ay +5 group (N549) p
57.6 (43-74)
.04 x106 (2.8 x108,
1.9 x106)
12 (10-14) <
14 (9-63)
20 (41.7%)
25 (52.1%) <<35kg/m2 114 13 127
35-39 kg/m2 88 0 88
>39 kg/m2 12 5 17
Total 214 18 232p<.0001 (Chi-Square).
In the quartile analysis, there was one death in the lowest quartile, no
deaths in the second quartile, three deaths in the third quartile and
two deaths in the fourth quartile.
Conclusion:Our results mirror what other studies have found; that
increasing obesity is especially significant in a range above 30-35 kg/
M2 based solely on BMI classification. Our quartile analysis appears
to demonstrate a steep slope over our median (33.9kg/M2).
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RETROSPECTIVE COMPARISON OF DAY15 VERSUS DAY13 INITIATION
OF G-CSF IN MULTIPLE MYELOMA PATIENTS RECEIVING AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Koralkar, R., Hundley, B., Donna, S.E., Vaughan, W.P. University of
Alabama at BIrmingham, Birmingham, AL
Background: Filgrastim (G-CSF) administration after autologous
hematopoietic stem cell transplant (aHSCT) is routinely used to
shorten duration of neutropenia and risk of infection. The optimum
post transplant Day for startingG-CSF is not standardized.We have
historically used aHSCTDay13, but others have reported good re-
sults using Day 15.
Methods: Beginning 15 May 2009, patients with multiple myeloma
(MM) transplanted with myeloblative doses of melphalan and an
aHSCT24hours later receivedGCSF(250mg/m2) subcutaneouslydaily
fromDay15 until absolute granulocyte count (AGC) of 2000/mL.We
performed a validation after 49 patients comparing time to engraftment
of platelets and neutrophils compared to the immediately preceding 98
control patients given daily gCSF from Day 13 to the same AGC
endpoint.Additional endpoints includedstomatitis, transfusion support,
incidence of neutropenic fever, length of day, and 30 day mortality.
Results: There was no significant difference in number of CD341
cells infused among the two groups and there was no 30 day mortality
in either group.TheDay13 patients achievedneutrophil engraftment
a median of one day shorter than the Day15 patients (p\0.001, log-
rank). Median time to platelet recovery of more than 50  109/L was
two days earlier in Day 13 Group than Day 15 Group (p 5 0.02 in
log rank test). However, the rate of neutropenic fever rate was signifi-
cantly higher inDay13Group compared toDay15Group (62% vs.
42%, p 5 0.019). The rate of stomatitis was also higher in Day 13
Group compared to Day15 Group (82.7% vs. 52.1%, p5\0.001).Value
0.29†
0.79†
0.001*
0.023*
0.019†
0.001†Conclusion: Day 13 Administration of G-CSF provides early en-
graftment but there is increased rates for fever, stomatitis. The ap-
parent illogic of more neutropenic fever with faster white blood
cell (WBC) engraftment may be explained by better infectious dis-
ease prophylaxis in the more recent group.140
IMPACT OF CD34 CELL DOSE ON PLATELET ENGRAFTMENT AND
PLATELET TRANSFUSIONS FOLLOWING AUTOLOGOUS HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Shariatmadar, S.1, Pereira, D.2, Smith, R.2, Goodman, M.2 1University
of Miami Miller School of Medicine/Jackson Memorial Medical Center,
Miami, FL; 2University of Miami Miller School of Medicine/Jackson
Memorial Medical Center, Miami, FL
Introduction: Maximizing the CD34 cell content of the graft has
been reported to lead to faster platelet engraftment and lower
requirement for platelet transfusions in patients undergoing autolo-
gous stem cell transplantation (A-HSCT). We evaluated the impact
of CD34 cell dose on platelet recovery and transfusion requirements
in 114 consecutive adults undergoing A-HSCT with a CD34 cell
dose of . 2  106/kg recipient body weight (BW) infused.
Methods: From January 2007 to March 2010, 114 adults with NHL
(n: 45), multiple myeloma (n: 44), Hodgkin’s disease (n: 23) and AML
(n: 2) underwent apheresis (range: 1-7) and A-HSCT. Patients were
categorized in to 3 groups based on the CD341 cell dose transplanted
[group 1: 2.0-2.99  106 (n: 55), group 2: 3.0-5.0  106 (n: 38) and
group 3: . 5  106 CD34/kg recipient BW (n: 21)]. Neutrophil
and Platelet engraftment (platelet count. 20,000/ul for 2 consecutive
days without platelet support) and transfusion requirements post-
transplant were evaluated and correlated with patient’s age, diagnosis
and number of apheresis.
Results: Median neutrophil engraftment following transplantation
was 11 days in all groups, while median platelet engraftment was 14
days in group 1 and 13 days in groups 2 and 3. Platelet recovery by
days 30 and 60 was 90.7%/96.3% in group 1, 94.7%/100% in group
2, 90.5%/95.2% in group 3. Two patients with NHL in group 1
(3.6%) and one with AML in group 3 (4.8%) were platelet-dependent
. 60 days post-transplantation. One patient withNHL in group 1 ex-
pired on day 6 from transplant-related complications.Median platelet
transfusions were 3 doses of platelets in group 1 and 2 doses in other
groups. Patient’s age, diagnosis and number of apheresis did not affect
30 and 60 day platelet recovery/transfusions post-transplant. Nine pa-
tients (7.9%) received plerixafor-mobilized transplants with median
platelet engraftment 14 days post-transplant.
Conclusion: CD34 cell dose did not significantly impact platelet re-
covery and transfusion requirements post-transplantation with rapid
platelet recovery achievable with CD34 cell dose . 2  106/kg rec
BW. Other factors including the number of platelet precursors in
the transplanted product rather than CD34 cell dose may be a more
important indicator of platelet recovery post-transplantation.141
EFFICACY AND SAFETY OF HEMATOPOIETIC STEM CELL REMOBILIZA-
TION WITH PLERIXAFOR (MOZOBIL) 1 G-CSF IN PATIENTS WITH
GERM CELL TUMOR
Schriber, J.1, Horwitz, M.2, Libby, E.3, Huebner, D.4, Mody, P.D.4,
Holman, P. 1Banner Blood and Marrow Transplant Program, Phoe-
nix, AZ; 2Duke University Medical Center, Durham, NC; 3UNM
Cancer Center, Albuquerque, NM; 4Genzyme Corporation, Cam-
bridge, MA
Autologous hematopoietic stem cell transplantation can be cura-
tive for patients (pts) with germ cell tumors (GCT). Many such pts
are heavily pretreated. Moreover, most protocols call for tandem
transplant requiring higher cell yields. This creates a situation
where many pts are unable to successfully mobilize adequate cells.
Mobilization with plerixafor (P)1 G-CSF (G) is safe and effective
for pts with myeloma and lymphoma. Herein we describe the safety
S206 Poster Session Iand efficacy of P 1 G in pts with GCT who had previously failed
collection.
This is a retrospective analysis of pts withGCT enrolled in theUS
plerixafor compassionate use program. In this trial, pts with previous
mobilization failure (defined as the inability to collect $ 2x106
CD341 cells/kg or to achieve an adequate peripheral blood (PB)
count), were remobilized with P1G. G (10mg/kg SC) was given ev-
ery morning for 5 days. P (0.24 mg/kg SC) was given in the evening
onDay 4,11 hours prior to apheresis the next day. P, G, and apher-
esis were repeated until pts collected $ 2x106 CD341 cells/kg.
Records of 21 males with GCTwere analyzed. Median age was 35
years. Previous mobilization regimens included growth factor (GF)
alone in 14 (67%) and GF 1 chemotherapy in 7 (33%) pts; 17
(81%) pts failed to collect theminimum transplantable cell dose (me-
dian yield: 1.35 (range, 0.33 - 2.1) x106 CD341 cells/kg); 4 (19%) pts
did not undergo apheresis due to low PB CD341 cells. Remobiliza-
tion with P1 G resulted in a median yield of 3.2x106 CD341 cells/
kg. Seventeen (81%) pts collected$ 2x106 and 9 (43%) pts collected
$ 4x106 CD341 cells/kg in a median of 2 (range 1-3) and 3 (range 1-
4) days, respectively. Sixteen (76%) pts proceeded to transplant; 8
(38%) pts received tandem transplants. Median times to neutrophil
and platelet engraftment were 11 and 21 days, for single transplant
and 10.5 and 24 days, for tandem transplants. Drug-related adverse
events were observed in 8 (38%) pts; most were mild and commonly
included diarrhea (n 5 3), nausea (n 5 2), injection site reactions
(n 5 2), chills (n 5 2) and bone pain (n 5 2). There were no serious
adverse events.
The majority of pts with GCT who had failed prior mobilization
with GF6 chemotherapy could collect an adequate number of HSC
with P 1 G for at least 1 transplant. Using this approach 76% and
38% of pts could undergo a single and tandem transplant respec-
tively. None of these pts would have collected sufficient cells to
proceed to transplant without this approach.
Table 1. Remobilization OutcomesNo. of Patients 21Median age (range) 35 (20-51)Gender, male (%) 21 (100)Median CD34+ cells/kg  106 Collected (range) 3.2 (0.76 - 15.80)
No. of patients collecting$2  106 CD34+ cells/kg (%) 17 (81)
No. of patients collecting$4  106 CD34+ cells/kg (%) 9 (43)
Median days to collect$2 106 CD34+ cells/kg (range) 2 (1-3)
Median days to collect$4 106 CD34+ cells/kg (range) 3 (1-4)
No. of patients proceeding to single transplant (%) 16 (76patients proceeding
to single transplant (%))No. of patients proceeding to tandem transplant (%) 8 (38)Median days to neutrophil engraftment (range) 11 (9-18)*Median days to platelet engraftment (range) 20 (12-48)**No significant differences were seen in engraftment times between the
first and second transplant142
BUMELTT (BUSULPHAN, MELPHALAN, AND THIOTEPA) AS A PREPARA-
TIVE REGIMEN PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION
IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN’S DISEASE DOES
NOT OFFER ANY ADVANTAGE OVER MORE STANDARD REGIMENS LIKE
BEAM OR BEAC
Ganguly, S.1, Jain, V.2, Divine, C.L.1, Ajitawi, O.1, Abhyankar, S.1,
McGuirk, J.P.1 1University of Kansas Center, Kansas City, KS; 2Univer-
sity of Kansas Medical Center, Kansas City, KS
High-dose chemotherapy with carmustine, etoposide, cytosine ara-
binoside, and melphalan (BEAM) or cyclophosphamide (BEAC) fol-
lowed by autologous hematopoietic stem cell transplantation (ASCT)
represents a standard therapy for many patients with relapsed Hodg-
kin’s disease (HD). Amore intense preparative regimen like BuMelTT
(busulphan, melphalan, and thiotepa) has been applied in patients with
hematological malignancies with variable success and toxicity.
In an attempt to compare efficacy, outcome, and toxicity of
BuMelTT versus more standard BEAM or BEAC in patients with
HDundergoing ASCT, we retrospectively evaluated our center’s ex-
perience between January 2008 and April 2010.Out of 9 patients in the BuMelTT group (median age 30y; range
19-46y), 8 patients (89%) had active disease and out of 14 patients in
the BEAM (n 5 11)/ BEAC (n 5 3) group (median age 33y; range
20-67y), 10 patients (72%) had active disease at the time of transplan-
tation. The probability of disease-free survival (DFS) (55% in
BuMelTT versus 43% in BEAM/BEAC group; p5 0.6) and overall
survival (OS) (83% in BuMelTT versus 85% in BEAM/BEAC
group; p 5 0.4) were comparable in both the groups at one year
with a median duration of follow-up of 17 months. Probability of
DFS (BuMelTT 43%; BEAM/BEAC 18%; p 5 0.5) and OS
(BuMelTT 83%; BEAM/BEAC 85%; p 5 0.9) at one year when
transplanted with active disease were comparable between the two
groups as well. No patient died from transplant-related complica-
tions.More patients in the BuMelTTgroup (100%) developed grade
2 or greater mucositis compared to patients in the BEAM/BEAC
group (50%). Average length of stay was longer in BuMelTT group
(median 21 days; range 18-22) compared to BEAM/BEAC group
(median 18 days; range 9-36) (p 5 0.016) with more observed inpa-
tient cost with BuMelTT (mean: $51,650; range $33,242-166,867
versus $40,730; range $22, 661-63,668) (p 5 0.03).
In conclusion, BuMelTT as a preparative regimen was not supe-
rior compared tomore standard BEAMor BEAC in patients with re-
lapsed/refractory HD. BuMelTT chemotherapy is associated with
more GI toxicity, longer hospital stay and greater observed cost.143
MEASUREMENT OF ALDEHYDE DEHYDROGENASE ACTIVITY IN
ALLOGENEIC OR AUTOLOGOUS PERIPHERAL STEMCELL GRAFTS MAY
SUBSTITUTE TIME CONSUMING CELLS CULTURES
Leitner, G.C.1, Bartuschka, A.1, Schulenburg, A.2 1TransfusionMedicine,
Vienna, Austria; 2BMT Unit, Vienna, Austria
Background: Autologous and allogeneic stem cell (PBSC) trans-
plantations are a curative option in hematologic-oncologic diseases.
In daily routine stem cell harvests are measured on CD34 antigen
and vitality. The colony-forming ability (CFU) of the harvested stem
cells is predictive for the hematological engraftment but results are
not available until 14 days. Themetabolic marker aldehyde dehydro-
genase (ALDH) was found in hematological vital stem cells. Former
investigations described a correlation between ALDH activity of
harvested stem cells and CFU. Therefore this assay may be useful
for characterizing PBSC graft quality, especially as the results are
available simultaneously to the CD34 and vitality data.
In a prospective analysis we investigated the ALDH activity in
freshly collected PBSC and in frozen products and correlated the re-
sults with the number of CFUs
Material and Methods: In the allogeneic setting 16 PBSC harvests
from 13 donors, 7 males and 6 females, median age of 45 years (24-
60) and in the autologous setting 42 products of 25 patients, 15males
and 10 females, median age 52 years (21-67) were investigated.
Stem cell harvests were measured on CD341 cells and vitality
with 7 AAD by flow cytometry according to the ISHAGE protocol.
ALDH activity was also determined by FACS analysis using the Al-
deflourkit (Stemcell Technologies, France) according to the man-
ufacture’s instructions.
Analyses were done in freshly collected PBSCs and in cryopre-
served products before transplantation or after 6 months of storage,
respectively.
Results:The allogeneic stem cell grafts had a CD34 purity of 0.74%
(0.47-1.83), an ALDH activity of 0.7% (0.45-2.18) and a CFU con-
tent of 236  105 (28-480).
The autologous grafts showed aCD34purityof 0.6% (0.11-7.63), an
ALDH activity of 0.59% (0.15-8.89) and CFUs of 139 105 (0-892).
CFUs and ALDH activity showed a higher correlation than CFUs
and CD341 cells in the autologous grafts (R0.73 vs R0.40) No such
difference was observed in the allogeneic grafts. Low initial ALDH
activity (below 0.20%) was combined with low numbers and low
recovery of CFUs after thawing frozen PBSC. No correlation was
observed between vitality and CFUs in both settings.
Conclusion: Measuring of ALDH activity in PBSCs may alleviate
the PBSC harvest management in patients with CD34 yields near
the threshold for a successful transplantation.
